Cargando…
Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver and has an overall five-year survival rate of less than twenty percent. For patients with unresectable disease, evolving liver-directed locoregional therapies provide efficacious treatment across the spectrum of disease st...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613749/ https://www.ncbi.nlm.nih.gov/pubmed/34887643 http://dx.doi.org/10.3748/wjg.v27.i43.7462 |
_version_ | 1784603702007431168 |
---|---|
author | Makary, Mina S Ramsell, Stuart Miller, Eric Beal, Eliza W Dowell, Joshua D |
author_facet | Makary, Mina S Ramsell, Stuart Miller, Eric Beal, Eliza W Dowell, Joshua D |
author_sort | Makary, Mina S |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver and has an overall five-year survival rate of less than twenty percent. For patients with unresectable disease, evolving liver-directed locoregional therapies provide efficacious treatment across the spectrum of disease stages and via a variety of catheter-directed and percutaneous techniques. Goals of locoregional therapies in HCC may include curative intent in early-stage disease, bridging or downstaging to surgical resection or transplantation for early or intermediate-stage disease, and local disease control and palliation in advanced-stage disease. This review explores the outcomes of chemoembolization, bland embolization, radioembolization, and percutaneous ablative therapies. Attention is also given to prognostic factors related to each of the respective techniques, as well as future directions of locoregional therapies for HCC. |
format | Online Article Text |
id | pubmed-8613749 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-86137492021-12-08 Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons Makary, Mina S Ramsell, Stuart Miller, Eric Beal, Eliza W Dowell, Joshua D World J Gastroenterol Review Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver and has an overall five-year survival rate of less than twenty percent. For patients with unresectable disease, evolving liver-directed locoregional therapies provide efficacious treatment across the spectrum of disease stages and via a variety of catheter-directed and percutaneous techniques. Goals of locoregional therapies in HCC may include curative intent in early-stage disease, bridging or downstaging to surgical resection or transplantation for early or intermediate-stage disease, and local disease control and palliation in advanced-stage disease. This review explores the outcomes of chemoembolization, bland embolization, radioembolization, and percutaneous ablative therapies. Attention is also given to prognostic factors related to each of the respective techniques, as well as future directions of locoregional therapies for HCC. Baishideng Publishing Group Inc 2021-11-21 2021-11-21 /pmc/articles/PMC8613749/ /pubmed/34887643 http://dx.doi.org/10.3748/wjg.v27.i43.7462 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Review Makary, Mina S Ramsell, Stuart Miller, Eric Beal, Eliza W Dowell, Joshua D Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons |
title | Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons |
title_full | Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons |
title_fullStr | Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons |
title_full_unstemmed | Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons |
title_short | Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons |
title_sort | hepatocellular carcinoma locoregional therapies: outcomes and future horizons |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613749/ https://www.ncbi.nlm.nih.gov/pubmed/34887643 http://dx.doi.org/10.3748/wjg.v27.i43.7462 |
work_keys_str_mv | AT makaryminas hepatocellularcarcinomalocoregionaltherapiesoutcomesandfuturehorizons AT ramsellstuart hepatocellularcarcinomalocoregionaltherapiesoutcomesandfuturehorizons AT millereric hepatocellularcarcinomalocoregionaltherapiesoutcomesandfuturehorizons AT bealelizaw hepatocellularcarcinomalocoregionaltherapiesoutcomesandfuturehorizons AT dowelljoshuad hepatocellularcarcinomalocoregionaltherapiesoutcomesandfuturehorizons |